首页> Frontiers in pharmacology> A Combined Human in Silico and CRISPR/Cas9-Mediated in Vivo Zebrafish Based Approach to Provide Phenotypic Data for Supporting Early Target Validation.

A Combined Human in Silico and CRISPR/Cas9-Mediated in Vivo Zebrafish Based Approach to Provide Phenotypic Data for Supporting Early Target Validation.

导出 LinkOut

翻译打印收藏纠错

第一作者： Matthew J,Winter

第一单位： Biosciences, College of Life and Environmental Sciences, University of Exeter, Exeter, United Kingdom.

作者： Matthew J,Winter ^[1] ; Yosuke,Ono ^[2] ; Jonathan S,Ball ^[1] ; Anna,Walentinsson ^[3] ; Erik,Michaelsson ^[4] ; Anna,Tochwin ^[1] ; Steffen,Scholpp ^[2] ; Charles R,Tyler ^[1] ; Steve,Rees ^[5] ; Malcolm J,Hetheridge ^[1] ; Mohammad,Bohlooly-Y ^[6]

作者单位： Biosciences, College of Life and Environmental Sciences, University of Exeter, Exeter, United Kingdom. ^[1] Living Systems Institute, College of Life and Environmental Sciences, University of Exeter, Exeter, United Kingdom. ^[2] Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. ^[3] Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. ^[4] Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom. ^[5] Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. ^[6]

关键词 CRISPR/Cas9 drug target identification and validation heart failure human whole exome sequencing zebrafish

DOI 10.3389/fphar.2022.827686

PMID 35548346

发布时间 2025-05-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交